Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E10H autologous natural killer cells injection
- Development stage
- Unknown
- Lead developer
- Guangzhou Double Bioproducts
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
E10H is an autologous natural killer (NK) cell therapy developed by Guangzhou Dabio Biological Products. The treatment involves the ex vivo expansion and activation of NK cells derived from the patient's own peripheral blood. Once re-infused, these activated NK cells are intended to recognize and destroy malignant cells in patients with advanced gastrointestinal cancers, including gastric and colorectal cancer. The therapy is currently being evaluated in a Phase I clinical trial (CTR20222083) to assess its safety, tolerability, and preliminary efficacy in patients who have failed standard treatment options.
- Other names
- E10H autologous natural killer cellsE-10H autologous natural killer cellsE 10H autologous natural killer cells
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on E10H autologous natural killer cells injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E10H autologous natural killer cells injection.